Leigh Zawel

USPTO Granted Patents = 14 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 6)

Average Co-Inventor Count = 6.0

ph-index = 4

Forward Citations = 87(Granted Patents)

Location History:

Cambridge, MA (US) (2011 - 2013)
Hingham, MA (US) (2008 - 2014)
Weston, MA (US) (2017 - 2022)

Company Filing History:

Dana-farber-cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11382905 - Immunomodulation by IAP inhibitors (2022-07-12),

2. 10786491 - Immunomodulation by IAP inhibitors (2020-09-29),

3. 9750729 - Immunomodulation by IAP inhibitors (2017-09-05),

4. 8906936 - Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof (2014-12-09),

5. 8552003 - (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses (2013-10-08),

6. 8546336 - SMAC peptidometics useful as IAP inhibitors (2013-10-01),

7. 8492429 - Combination of IAP inhibitors and FLT3 inhibitors (2013-07-23),

8. 8338440 - Inhibitors of IAP (2012-12-25),

9. 8207183 - Inhibitors of IAP (2012-06-26),

10. 8058272 - Organic compounds (2011-11-15),

11. 8048886 - Substituted pyrazine-3-one-derivatives as IAP inhibitors (2011-11-01),

12. 8044209 - Pyrrolydine derivatives as IAP inhibitors (2011-10-25),

13. 7989441 - Organic compounds (2011-08-02),

14. 7419975 - Organic compounds (2008-09-02),

Title: Innovations and Contributions of Inventor Leigh Zawel

Introduction

Leigh Zawel is a prominent inventor based in Hingham, MA, known for his significant contributions to the field of immunology. With a total of 14 patents to his name, Zawel has made remarkable advancements in the development of immune adjuvants and therapeutic methods.

Latest Patents

One of Zawel's latest patents focuses on "Immunomodulation by IAP inhibitors." This invention is directed towards immune adjuvants that contain IAP inhibitors, including Smac mimetics. The patent outlines pharmaceutical compositions and vaccines that incorporate an IAP inhibitor along with an antigen. Additionally, it provides methods for enhancing immune responses through the administration of IAP inhibitors. These methods also include approaches for treating or preventing cancer, infections, autoimmune disorders, and for potentiating cytokine or antibody production.

Career Highlights

Throughout his career, Leigh Zawel has worked with notable organizations such as Novartis AG and Dana-Farber Cancer Institute Inc. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Zawel has had the opportunity to work alongside esteemed colleagues, including Christopher Sean Straub and Run-Ming David Wang. These collaborations have further enriched his research and innovation efforts.

Conclusion

Leigh Zawel's contributions to immunology through his patents and collaborations highlight his role as a key innovator in the field. His work continues to influence advancements in immune therapies and treatments.

This text is generated by artificial intelligence and may not be accurate.